SCHEMBL15425985

SCHEMBL15425985

Cc1cc2c(cn1)c(=O)c(C(=O)O)cn2C(C)(C)CC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.38
MEN1 O00255 1/20 0.38
ABCC4 O15439 1/20 0.38
PKM P14618 1/20 0.38
PTGS1 P23219 1/20 0.38
KMT2A Q03164 1/20 0.38
CASP1 P29466 1/20 0.35
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 3/20 0.34
HPGD P15428 2/20 0.34
HSD17B10 Q99714 2/20 0.34
TSHR P16473 1/20 0.34
RAB9A P51151 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
APEX1 P27695 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
TOP2A P11388 4/20 0.33
TOP2B Q02880 4/20 0.33
PIK3CG P48736 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12611022 0.86 PIK3CG (0.40) LMNAMEN1ABCC4PKMPTGS1
SCHEMBL15425988 0.81 CNR2 (0.46) LMNAALDH1A1KDM4EHPGDTSHR
SCHEMBL7128889 0.78 LMNA (0.37) LMNAMEN1ABCC4PKMPTGS1
SCHEMBL12611024 0.72 PIK3CG (0.39) LMNAMEN1KMT2ACASP1ALDH1A1
SCHEMBL7489676 0.70 ALDH1A1 (0.47) LMNAMEN1KMT2AALDH1A1KDM4E
SCHEMBL15999549 0.68 KDM4E (0.39) LMNAMEN1ABCC4PKMPTGS1
SCHEMBL20031279 0.67 KMT2A (0.43) LMNAMEN1KMT2AALDH1A1KDM4E
SCHEMBL7128784 0.67 LMNA (0.43) LMNAMEN1PKMKMT2AALDH1A1
SCHEMBL7845387 0.64 ALDH1A1 (0.46) LMNAMEN1KMT2AALDH1A1KDM4E
SCHEMBL7608724 0.64 ALDH1A1 (0.46) LMNAMEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140018384-A1 QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE PRONOXIS AB (SE) 2014-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018384-A1 QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE NOX4, NOX1, CYBB LMNA 3790/4885MEN1 2822/4885ABCC4 1474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.